Takeda Pharmaceutical Co Ltd
TAKNYSECIK 1395064Healthcare
Revenue is not reported in this company’s XBRL financial statements.
Latest quarter: not reported
Last eight quarters
Full statements| Line item | Unit | Shape over the periods |
|---|---|---|
| Revenue | $ | |
| Gross margin | % | |
| Operating margin | % | |
| Net margin | % | |
| Diluted EPS | $ per share | |
| Free cash flow | $ |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Last five fiscal years
| Line item | Unit | FY20212021-03-31 | FY20222022-03-31 | FY20232023-03-31 | FY20242024-03-31 | FY20252025-03-31 | Shape over the periods |
|---|---|---|---|---|---|---|---|
| Revenue | $bn | 3,198Revenue, FY2021, twelve months to 2021-03-31JPY 3.20tn. XBRL concept ifrs-full:Revenue. 20-F filed 2023-06-28, accession 0001395064-23-000072.Report this figure | 3,569Revenue, FY2022, twelve months to 2022-03-31JPY 3.57tn. XBRL concept ifrs-full:Revenue. 20-F filed 2024-06-26, accession 0001395064-24-000086.Report this figure | 4,027Revenue, FY2023, twelve months to 2023-03-31JPY 4.03tn. XBRL concept ifrs-full:Revenue. 20-F filed 2025-06-25, accession 0001395064-25-000095.Report this figure | 4,264Revenue, FY2024, twelve months to 2024-03-31JPY 4.26tn. XBRL concept ifrs-full:Revenue. 20-F filed 2025-06-25, accession 0001395064-25-000095.Report this figure | 4,582Revenue, FY2025, twelve months to 2025-03-31JPY 4.58tn. XBRL concept ifrs-full:Revenue. 20-F filed 2025-06-25, accession 0001395064-25-000095.Report this figure | |
| Gross margin | % | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | not reported (Gross profit not reported) | |
| Operating margin | % | 15.9%Operating margin, FY2021, twelve months to 2021-03-31. operating income / revenueOperating income: JPY 509.27bn. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2023-06-28, accession 0001395064-23-000072.Revenue: JPY 3.20tn. XBRL concept ifrs-full:Revenue. 20-F filed 2023-06-28, accession 0001395064-23-000072.Report this figure | 12.9%Operating margin, FY2022, twelve months to 2022-03-31. operating income / revenueOperating income: JPY 460.84bn. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2024-06-26, accession 0001395064-24-000086.Revenue: JPY 3.57tn. XBRL concept ifrs-full:Revenue. 20-F filed 2024-06-26, accession 0001395064-24-000086.Report this figure | 12.2%Operating margin, FY2023, twelve months to 2023-03-31. operating income / revenueOperating income: JPY 490.50bn. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2025-06-25, accession 0001395064-25-000095.Revenue: JPY 4.03tn. XBRL concept ifrs-full:Revenue. 20-F filed 2025-06-25, accession 0001395064-25-000095.Report this figure | 5.0%Operating margin, FY2024, twelve months to 2024-03-31. operating income / revenueOperating income: JPY 214.07bn. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2025-06-25, accession 0001395064-25-000095.Revenue: JPY 4.26tn. XBRL concept ifrs-full:Revenue. 20-F filed 2025-06-25, accession 0001395064-25-000095.Report this figure | 7.5%Operating margin, FY2025, twelve months to 2025-03-31. operating income / revenueOperating income: JPY 342.59bn. XBRL concept ifrs-full:ProfitLossFromOperatingActivities. 20-F filed 2025-06-25, accession 0001395064-25-000095.Revenue: JPY 4.58tn. XBRL concept ifrs-full:Revenue. 20-F filed 2025-06-25, accession 0001395064-25-000095.Report this figure | |
| Net margin | % | 11.8%Net margin, FY2021, twelve months to 2021-03-31. net income / revenueNet income: JPY 376.00bn. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2023-06-28, accession 0001395064-23-000072.Revenue: JPY 3.20tn. XBRL concept ifrs-full:Revenue. 20-F filed 2023-06-28, accession 0001395064-23-000072.Report this figure | 6.4%Net margin, FY2022, twelve months to 2022-03-31. net income / revenueNet income: JPY 230.06bn. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2024-06-26, accession 0001395064-24-000086.Revenue: JPY 3.57tn. XBRL concept ifrs-full:Revenue. 20-F filed 2024-06-26, accession 0001395064-24-000086.Report this figure | 7.9%Net margin, FY2023, twelve months to 2023-03-31. net income / revenueNet income: JPY 317.02bn. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2025-06-25, accession 0001395064-25-000095.Revenue: JPY 4.03tn. XBRL concept ifrs-full:Revenue. 20-F filed 2025-06-25, accession 0001395064-25-000095.Report this figure | 3.4%Net margin, FY2024, twelve months to 2024-03-31. net income / revenueNet income: JPY 144.07bn. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2025-06-25, accession 0001395064-25-000095.Revenue: JPY 4.26tn. XBRL concept ifrs-full:Revenue. 20-F filed 2025-06-25, accession 0001395064-25-000095.Report this figure | 2.4%Net margin, FY2025, twelve months to 2025-03-31. net income / revenueNet income: JPY 107.93bn. XBRL concept ifrs-full:ProfitLossAttributableToOwnersOfParent. 20-F filed 2025-06-25, accession 0001395064-25-000095.Revenue: JPY 4.58tn. XBRL concept ifrs-full:Revenue. 20-F filed 2025-06-25, accession 0001395064-25-000095.Report this figure | |
| Diluted EPS | $ per share | 238.96Diluted EPS, FY2021, twelve months to 2021-03-31JPY 238.96 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2023-06-28, accession 0001395064-23-000072.Report this figure | 145.87Diluted EPS, FY2022, twelve months to 2022-03-31JPY 145.87 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2024-06-26, accession 0001395064-24-000086.Report this figure | 201.94Diluted EPS, FY2023, twelve months to 2023-03-31JPY 201.94 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2025-06-25, accession 0001395064-25-000095.Report this figure | 91.16Diluted EPS, FY2024, twelve months to 2024-03-31JPY 91.16 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2025-06-25, accession 0001395064-25-000095.Report this figure | 67.23Diluted EPS, FY2025, twelve months to 2025-03-31JPY 67.23 per share. XBRL concept ifrs-full:DilutedEarningsLossPerShare. 20-F filed 2025-06-25, accession 0001395064-25-000095.Report this figure | |
| Free cash flow | $bn | 900Free cash flow, FY2021, twelve months to 2021-03-31. operating cash flow − capital expenditureOperating cash flow: JPY 1.01tn. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2023-06-28, accession 0001395064-23-000072.Capital expenditure: JPY 111.21bn. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2023-06-28, accession 0001395064-23-000072.Report this figure | 1,000Free cash flow, FY2022, twelve months to 2022-03-31. operating cash flow − capital expenditureOperating cash flow: JPY 1.12tn. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2024-06-26, accession 0001395064-24-000086.Capital expenditure: JPY 123.25bn. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2024-06-26, accession 0001395064-24-000086.Report this figure | 836Free cash flow, FY2023, twelve months to 2023-03-31. operating cash flow − capital expenditureOperating cash flow: JPY 977.16bn. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2025-06-25, accession 0001395064-25-000095.Capital expenditure: JPY 140.66bn. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2025-06-25, accession 0001395064-25-000095.Report this figure | 541Free cash flow, FY2024, twelve months to 2024-03-31. operating cash flow − capital expenditureOperating cash flow: JPY 716.34bn. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2025-06-25, accession 0001395064-25-000095.Capital expenditure: JPY 175.42bn. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2025-06-25, accession 0001395064-25-000095.Report this figure | 856Free cash flow, FY2025, twelve months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: JPY 1.06tn. XBRL concept ifrs-full:CashFlowsFromUsedInOperatingActivities. 20-F filed 2025-06-25, accession 0001395064-25-000095.Capital expenditure: JPY 200.79bn. XBRL concept ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. 20-F filed 2025-06-25, accession 0001395064-25-000095.Report this figure |
Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.
Insider purchases and sales
All insider transactionsThe last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.
No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.
No open-market purchases or sales by insiders are in coverage for this company.
Funds that report holding it
All fundsFrom each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.
| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|
| Capital Research Global Investors | 2026-06-30 | $309.3m | 19,297,680 | Added+193,461 | |
| FMR LLC | 2026-06-30 | $153.9m | 9,599,302 | Added+2,481,816 | |
| MORGAN STANLEY | 2026-06-30 | $112.1m | 6,994,924 | Added+525,324 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2026-06-30 | $97.0m | 6,050,771 | Reduced−374,213 | |
| GOLDMAN SACHS GROUP INC | 2026-06-30 | $82.2m | 5,125,032 | Reduced−493,696 | |
| BRANDES INVESTMENT PARTNERS, LP | 2026-06-30 | $72.8m | 4,539,347 | Added+108,705 | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 2026-06-30 | $59.8m | 3,732,924 | Added+616,613 | |
| BlackRock, Inc. | 2026-06-30 | $59.1m | 3,688,166 | Added+511,745 | |
| RENAISSANCE TECHNOLOGIES LLC | 2026-06-30 | $41.2m | 2,568,000 | Reduced−421,100 | |
| Qube Research & Technologies Ltd | 2026-06-30 | $35.4m | 2,207,432 | New+2,207,432 |
Recent filings
All 690 filingsReports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2906:49 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-29 | 0001395064-26-000345 |
| 2026-10-2906:33 ET | 6-K | Report of a foreign private issuerPeriod 2026-10-29 | 0001395064-26-000343 |
| 2026-09-1406:25 ET | 6-K | Report of a foreign private issuerPeriod 2026-09-14 | 0001395064-26-000337 |
| 2026-08-3121:10 ET | 6-K | Report of a foreign private issuerPeriod 2026-08-28 | 0001395064-26-000331 |
| 2026-08-0621:37 ET | 6-K | Report of a foreign private issuerPeriod 2026-08-05 | 0001395064-26-000329 |
| 2026-07-3006:01 ET | 6-K | Report of a foreign private issuerPeriod 2026-07-30 | 0001395064-26-000327 |
| 2026-07-0906:00 ET | 6-K | Report of a foreign private issuerPeriod 2026-07-09 | 0001395064-26-000280 |
| 2026-07-0806:02 ET | 6-K | Report of a foreign private issuerPeriod 2026-07-08 | 0001395064-26-000278 |
| 2026-06-2906:01 ET | 6-K | Report of a foreign private issuerPeriod 2026-06-29 | 0001395064-26-000189 |
| 2026-06-2606:32 ET | 6-K | Report of a foreign private issuerPeriod 2026-06-26 | 0001395064-26-000187 |
Latest annual report
Form 20-F for the fiscal year ended Mar 31, 2026Filed Jun 17, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.
Forecast league
Not in this season’s league. The league lists companies whose quarter has ended and whose results are not yet filed.This season’s league
About the filer
- CIK
- 1395064
- Tickers
- TAK, TKPHF
- Exchange
- NYSE
- SIC code
- 2834 Pharmaceutical Preparations
- Sector
- Healthcare
- Fiscal year ends
- not reported
- Incorporated in
- not reported
- Filer category
- Large accelerated filer
Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 18:41 ET. Listed shows no prices and gives no investment advice.